FDA accepts application for application for treatment of advanced renal cell carcinoma by Bavencio (avelumab) and Inlyta (Axitinib)
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
renal cell carcinoma is the most common type of kidney cancer, accounting for about 70% of patients with kidney cancer, accounting for 2% to 3% of all types of cancer patients in adultsAlthough there is a corresponding treatment for advanced renal cell carcinoma
the drug(http://, the prognosis of patients is still poorrecently, Merck Sherano and Pfizer announced thatFDA(http://has accepted the listing of Bavencio (avelumab) and Inlyta (aestini) for treatment of advanced renal cell carcinoma (sBLA), and granted priority review eligibility, PDUFA is scheduled for approval in June 2019In December 2017, the FDA qualified avelumab and axithinib for advanced RCC breakthrough therapythe sBLA is based primarily on data from the PHASE III JAVELIN Renal 101 studyavelumab clinical development project named JAVELIN, involving more than 30 clinicaltrial series(http://, enrolled more than 9000 patients, 15 different types of tumors, in addition to RCC, including breast cancer, stomach cancer/ gastroesophageal connectivity cancer, head and neck cancer, Merkel cell carcinoma, NSCLC, urinary skin cancer, etc
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
